Business Context and Reporting Period
This Form 8-K was filed by ReWalk Robotics Ltd. on June 29, 2018. The filing serves solely to disclose amendments to existing agreements with the President and Fellows of Harvard College regarding research collaboration and licensing for lightweight "soft suit" exoskeleton technologies.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The report details the following contractual updates:
- Original Agreements: Entered into on May 16, 2016, comprising a Research Collaboration Agreement and an Exclusive License Agreement with Harvard.
- Amendment No. 1 (Collaboration): Executed on May 1, 2017.
- Joint Amendment: Executed on April 1, 2018, consisting of Amendment No. 1 to the License Agreement and Amendment No. 2 to the Collaboration Agreement.
Outlook, Risks, and Unusual Items
Management Commentary: The collaboration focuses on developing technologies for lower limb disabilities, targeting stroke, multiple sclerosis, and mobility limitations for the elderly.
Confidentiality: Confidential treatment has been requested for portions of the amended agreements (Exhibits 10.1 and 10.2). The omitted portions were filed separately with the SEC under Rule 24b-2.
Emerging Growth Company Status: The registrant is identified as an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Key Facts for Investor Verification
- Verify the specific terms of the April 1, 2018, Joint Amendment by reviewing the confidential portions filed separately with the SEC.
- Confirm the scope of the exclusive, worldwide royalty-bearing license granted by Harvard.
- Monitor the progress of the "soft suit" exoskeleton development for the specified medical applications.